Amandine Manon
Research Subjects
Amandine Manon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Azher Hussain
Merck & Co., Lansdale, Pennsylvania
1 shared publication - Francine Attié de Castro
Certara, Paris 75008, France
1 shared publication - Jackie Kline
Amgen, Thousand Oaks, California
1 shared publication - Julie Bullock
Certara, Inc., Durham, North Carolina
1 shared publication - Karthik Venkatakrishnan
EMD Serono Research and Development Institute, Inc. Billerica Massachusetts USA
1 shared publication - Kyungho Jang
Cha Biotech, Seongnam 13488, Korea
1 shared publication
Latest Publications
- 4 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5237-5241
Oncology Combination Drug Development Strategies for Project Optimus
The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for single agents, but multiple oncology drugs are being developed for use in combination with other therapies. Dose optimization in the context of combination drug development is complex and requires a case-by-case approach. It necessitates commitment to the totality of available evidence, leveraging all relevant data on mechanism of action, nonclinical and clinical pharmacology, safety, and principles of model-informed drug development. In this article, we outline key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens. We illustrate important strategies for dose optimization in the combination setting using a range of hypothetical case examples that represent typical drug development scenarios. Close discussions and collaboration with regulators regarding the optimal approaches to these scenarios will continue to be critical.
- 4 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5237-5241
Oncology Combination Drug Development Strategies for Project Optimus
The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for single agents, but multiple oncology drugs are being developed for use in combination with other therapies. Dose optimization in the context of combination drug development is complex and requires a case-by-case approach. It necessitates commitment to the totality of available evidence, leveraging all relevant data on mechanism of action, nonclinical and clinical pharmacology, safety, and principles of model-informed drug development. In this article, we outline key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens. We illustrate important strategies for dose optimization in the combination setting using a range of hypothetical case examples that represent typical drug development scenarios. Close discussions and collaboration with regulators regarding the optimal approaches to these scenarios will continue to be critical.
- Open Access
- 1 January 2023
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 31 (3) , 125-130
What goes in the regulatory clinical pharmacology package for an oncolytic virus?
Yum SY, et al. Transl Clin Pharmacol. 2023 Sep;31(3):125-130. https://doi.org/10.12793/tcp.2023.31.e14
- 1 January 2023
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 31 (3) , 125-130
Open AccessWhat goes in the regulatory clinical pharmacology package for an oncolytic virus?
Yum SY, et al. Transl Clin Pharmacol. 2023 Sep;31(3):125-130. https://doi.org/10.12793/tcp.2023.31.e14